Alto Neuroscience (NYSE:ANRO) Trading Down 4.7% – Here’s What Happened

Alto Neuroscience, Inc. (NYSE:ANRO) shares dropped 4.7% during trading on Friday . The company traded as low as $30.51 and last traded at $30.7820. Approximately 57,990 shares were traded during trading, a decline of 84% from the average daily volume of 367,339 shares. The stock had previously closed at $32.30.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Chardan Capital reaffirmed a “buy” rating and set a $30.00 price objective on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Robert W. Baird cut their target price on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Wedbush boosted their price target on Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a research note on Thursday. Wall Street Zen cut Alto Neuroscience from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Finally, Zacks Research lowered Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 22nd. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Alto Neuroscience has a consensus rating of “Moderate Buy” and an average price target of $36.62.

Alto Neuroscience Stock Performance

The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -12.68 and a beta of 1.06. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. The stock’s 50-day simple moving average is $25.70 and its 200 day simple moving average is $22.68.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.08. Analysts expect that Alto Neuroscience, Inc. will post -3.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

A number of hedge funds and other institutional investors have recently bought and sold shares of ANRO. Invesco Ltd. bought a new position in Alto Neuroscience in the 1st quarter valued at $67,000. AQR Capital Management LLC bought a new stake in shares of Alto Neuroscience during the first quarter worth $52,000. Marshall Wace LLP increased its stake in shares of Alto Neuroscience by 9.9% in the second quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock valued at $2,062,000 after buying an additional 84,417 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Alto Neuroscience in the second quarter valued at $240,000. Finally, Bridgeway Capital Management LLC raised its holdings in shares of Alto Neuroscience by 85.9% in the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after buying an additional 25,000 shares during the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.